Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease.

Neumann U, Ufer M, Jacobson LH, Rouzade-Dominguez ML, Huledal G, Kolly C, Lüönd RM, Machauer R, Veenstra SJ, Hurth K, Rueeger H, Tintelnot-Blomley M, Staufenbiel M, Shimshek DR, Perrot L, Frieauff W, Dubost V, Schiller H, Vogg B, Beltz K, Avrameas A, Kretz S, Pezous N, Rondeau JM, Beckmann N, Hartmann A, Vormfelde S, David OJ, Galli B, Ramos R, Graf A, Lopez Lopez C.

EMBO Mol Med. 2018 Sep 17. pii: e9316. doi: 10.15252/emmm.201809316. [Epub ahead of print]

2.

G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice.

Novello S, Arcuri L, Dovero S, Dutheil N, Shimshek DR, Bezard E, Morari M.

Neurobiol Dis. 2018 Dec;120:21-33. doi: 10.1016/j.nbd.2018.08.018. Epub 2018 Aug 30.

PMID:
30172844
3.

Brain region-specific enhancement of remyelination and prevention of demyelination by the CSF1R kinase inhibitor BLZ945.

Beckmann N, Giorgetti E, Neuhaus A, Zurbruegg S, Accart N, Smith P, Perdoux J, Perrot L, Nash M, Desrayaud S, Wipfli P, Frieauff W, Shimshek DR.

Acta Neuropathol Commun. 2018 Feb 15;6(1):9. doi: 10.1186/s40478-018-0510-8.

4.

EBI2 regulates pro-inflammatory signalling and cytokine release in astrocytes.

Rutkowska A, Shimshek DR, Sailer AW, Dev KK.

Neuropharmacology. 2018 May 1;133:121-128. doi: 10.1016/j.neuropharm.2018.01.029. Epub 2018 Jan 31.

5.

BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology.

Peters F, Salihoglu H, Rodrigues E, Herzog E, Blume T, Filser S, Dorostkar M, Shimshek DR, Brose N, Neumann U, Herms J.

Acta Neuropathol. 2018 May;135(5):695-710. doi: 10.1007/s00401-017-1804-9. Epub 2018 Jan 11.

6.

BACE inhibition-dependent repair of Alzheimer's pathophysiology.

Keskin AD, Kekuš M, Adelsberger H, Neumann U, Shimshek DR, Song B, Zott B, Peng T, Förstl H, Staufenbiel M, Nelken I, Sakmann B, Konnerth A, Busche MA.

Proc Natl Acad Sci U S A. 2017 Aug 8;114(32):8631-8636. doi: 10.1073/pnas.1708106114. Epub 2017 Jul 24.

7.

Different Forms of AMPA Receptor Mediated LTP and Their Correlation to the Spatial Working Memory Formation.

Shimshek DR, Bus T, Schupp B, Jensen V, Marx V, Layer LE, Köhr G, Sprengel R.

Front Mol Neurosci. 2017 Jul 4;10:214. doi: 10.3389/fnmol.2017.00214. eCollection 2017.

8.

Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.

Longo F, Mercatelli D, Novello S, Arcuri L, Brugnoli A, Vincenzi F, Russo I, Berti G, Mabrouk OS, Kennedy RT, Shimshek DR, Varani K, Bubacco L, Greggio E, Morari M.

Acta Neuropathol Commun. 2017 Mar 14;5(1):22. doi: 10.1186/s40478-017-0426-8.

9.

Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibition Impairs Synaptic Plasticity via Seizure Protein 6.

Zhu K, Xiang X, Filser S, Marinković P, Dorostkar MM, Crux S, Neumann U, Shimshek DR, Rammes G, Haass C, Lichtenthaler SF, Gunnersen JM, Herms J.

Biol Psychiatry. 2018 Mar 1;83(5):428-437. doi: 10.1016/j.biopsych.2016.12.023. Epub 2016 Dec 26.

10.

Leucine-Rich Repeat Kinase 2 (Lrrk2)-Sensitive Na+/K+ ATPase Activity in Dendritic Cells.

Hosseinzadeh Z, Singh Y, Shimshek DR, van der Putten H, Wagner CA, Lang F.

Sci Rep. 2017 Jan 25;7:41117. doi: 10.1038/srep41117.

11.

Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition.

Schelle J, Häsler LM, Göpfert JC, Joos TO, Vanderstichele H, Stoops E, Mandelkow EM, Neumann U, Shimshek DR, Staufenbiel M, Jucker M, Kaeser SA.

Alzheimers Dement. 2017 Jun;13(6):701-709. doi: 10.1016/j.jalz.2016.09.005. Epub 2016 Oct 14.

PMID:
27750032
12.

Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases.

Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, Schweighauser M, Eninger T, Lambert M, Pilotto A, Shimshek DR, Neumann U, Kahle PJ, Staufenbiel M, Neumann M, Maetzler W, Kuhle J, Jucker M.

Neuron. 2016 Jul 20;91(2):494-496. doi: 10.1016/j.neuron.2016.07.007. Epub 2016 Jul 20. No abstract available.

13.

Longitudinal noninvasive magnetic resonance imaging of brain microhemorrhages in BACE inhibitor-treated APP transgenic mice.

Beckmann N, Doelemeyer A, Zurbruegg S, Bigot K, Theil D, Frieauff W, Kolly C, Moulin P, Neddermann D, Kreutzer R, Perrot L, Brzak I, Jacobson LH, Staufenbiel M, Neumann U, Shimshek DR.

Neurobiol Aging. 2016 Sep;45:50-60. doi: 10.1016/j.neurobiolaging.2016.05.009. Epub 2016 May 17.

14.

Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases.

Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, Schweighauser M, Eninger T, Lambert M, Pilotto A, Shimshek DR, Neumann U, Kahle PJ, Staufenbiel M, Neumann M, Maetzler W, Kuhle J, Jucker M.

Neuron. 2016 Jul 6;91(1):56-66. doi: 10.1016/j.neuron.2016.05.018. Epub 2016 Jun 9. Erratum in: Neuron. 2016 Jul 20;91(2):494-496.

15.

Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice.

Shimshek DR, Jacobson LH, Kolly C, Zamurovic N, Balavenkatraman KK, Morawiec L, Kreutzer R, Schelle J, Jucker M, Bertschi B, Theil D, Heier A, Bigot K, Beltz K, Machauer R, Brzak I, Perrot L, Neumann U.

Sci Rep. 2016 Feb 25;6:21917. doi: 10.1038/srep21917.

16.

A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.

Neumann U, Rueeger H, Machauer R, Veenstra SJ, Lueoend RM, Tintelnot-Blomley M, Laue G, Beltz K, Vogg B, Schmid P, Frieauff W, Shimshek DR, Staufenbiel M, Jacobson LH.

Mol Neurodegener. 2015 Sep 3;10:44. doi: 10.1186/s13024-015-0033-8.

17.

Leucine-rich repeat kinase 2-sensitive Na+/Ca2+ exchanger activity in dendritic cells.

Yan J, Almilaji A, Schmid E, Elvira B, Shimshek DR, van der Putten H, Wagner CA, Shumilina E, Lang F.

FASEB J. 2015 May;29(5):1701-10. doi: 10.1096/fj.14-264028. Epub 2015 Jan 21.

PMID:
25609428
18.

Formaldehyde-fixed brain tissue from spontaneously ill α-synuclein transgenic mice induces fatal α-synucleinopathy in transgenic hosts.

Schweighauser M, Bacioglu M, Fritschi SK, Shimshek DR, Kahle PJ, Eisele YS, Jucker M.

Acta Neuropathol. 2015 Jan;129(1):157-9. doi: 10.1007/s00401-014-1360-5. Epub 2014 Nov 4. No abstract available.

PMID:
25367384
19.

Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging.

Longo F, Russo I, Shimshek DR, Greggio E, Morari M.

Neurobiol Dis. 2014 Nov;71:62-73. doi: 10.1016/j.nbd.2014.07.013. Epub 2014 Aug 6.

20.

Imaging of cerebrovascular pathology in animal models of Alzheimer's disease.

Klohs J, Rudin M, Shimshek DR, Beckmann N.

Front Aging Neurosci. 2014 Mar 13;6:32. doi: 10.3389/fnagi.2014.00032. eCollection 2014. Review.

21.

Surfactant secretion in LRRK2 knock-out rats: changes in lamellar body morphology and rate of exocytosis.

Miklavc P, Ehinger K, Thompson KE, Hobi N, Shimshek DR, Frick M.

PLoS One. 2014 Jan 21;9(1):e84926. doi: 10.1371/journal.pone.0084926. eCollection 2014.

22.

Mutant huntingtin gene-dose impacts on aggregate deposition, DARPP32 expression and neuroinflammation in HdhQ150 mice.

Young D, Mayer F, Vidotto N, Schweizer T, Berth R, Abramowski D, Shimshek DR, van der Putten PH, Schmid P.

PLoS One. 2013 Sep 23;8(9):e75108. doi: 10.1371/journal.pone.0075108. eCollection 2013.

23.

Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2.

Troxler T, Greenidge P, Zimmermann K, Desrayaud S, Drückes P, Schweizer T, Stauffer D, Rovelli G, Shimshek DR.

Bioorg Med Chem Lett. 2013 Jul 15;23(14):4085-90. doi: 10.1016/j.bmcl.2013.05.054. Epub 2013 May 24.

PMID:
23768909
24.

Fragments of HdhQ150 mutant huntingtin form a soluble oligomer pool that declines with aggregate deposition upon aging.

Marcellin D, Abramowski D, Young D, Richter J, Weiss A, Marcel A, Maassen J, Kauffmann M, Bibel M, Shimshek DR, Faull RL, Bates GP, Kuhn RR, Van der Putten PH, Schmid P, Lotz GP.

PLoS One. 2012;7(9):e44457. doi: 10.1371/journal.pone.0044457. Epub 2012 Sep 12.

25.

Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening.

Bidinosti M, Shimshek DR, Mollenhauer B, Marcellin D, Schweizer T, Lotz GP, Schlossmacher MG, Weiss A.

J Biol Chem. 2012 Sep 28;287(40):33691-705. Epub 2012 Jul 27.

26.

High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain.

Herzig MC, Bidinosti M, Schweizer T, Hafner T, Stemmelen C, Weiss A, Danner S, Vidotto N, Stauffer D, Barske C, Mayer F, Schmid P, Rovelli G, van der Putten PH, Shimshek DR.

PLoS One. 2012;7(5):e36581. doi: 10.1371/journal.pone.0036581. Epub 2012 May 15.

27.

Excess α-synuclein worsens disease in mice lacking ubiquitin carboxy-terminal hydrolase L1.

Shimshek DR, Schweizer T, Schmid P, van der Putten PH.

Sci Rep. 2012;2:262. doi: 10.1038/srep00262. Epub 2012 Feb 13.

28.

Neuropathology in mice expressing mouse alpha-synuclein.

Rieker C, Dev KK, Lehnhoff K, Barbieri S, Ksiazek I, Kauffmann S, Danner S, Schell H, Boden C, Ruegg MA, Kahle PJ, van der Putten H, Shimshek DR.

PLoS One. 2011;6(9):e24834. doi: 10.1371/journal.pone.0024834. Epub 2011 Sep 26.

29.

LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice.

Herzig MC, Kolly C, Persohn E, Theil D, Schweizer T, Hafner T, Stemmelen C, Troxler TJ, Schmid P, Danner S, Schnell CR, Mueller M, Kinzel B, Grevot A, Bolognani F, Stirn M, Kuhn RR, Kaupmann K, van der Putten PH, Rovelli G, Shimshek DR.

Hum Mol Genet. 2011 Nov 1;20(21):4209-23. doi: 10.1093/hmg/ddr348. Epub 2011 Aug 9.

30.

The HSP70 molecular chaperone is not beneficial in a mouse model of alpha-synucleinopathy.

Shimshek DR, Mueller M, Wiessner C, Schweizer T, van der Putten PH.

PLoS One. 2010 Apr 2;5(4):e10014. doi: 10.1371/journal.pone.0010014.

31.

Synaptic inhibition in the olfactory bulb accelerates odor discrimination in mice.

Abraham NM, Egger V, Shimshek DR, Renden R, Fukunaga I, Sprengel R, Seeburg PH, Klugmann M, Margrie TW, Schaefer AT, Kuner T.

Neuron. 2010 Feb 11;65(3):399-411. doi: 10.1016/j.neuron.2010.01.009.

32.

Forebrain-specific glutamate receptor B deletion impairs spatial memory but not hippocampal field long-term potentiation.

Shimshek DR, Jensen V, Celikel T, Geng Y, Schupp B, Bus T, Mack V, Marx V, Hvalby Ø, Seeburg PH, Sprengel R.

J Neurosci. 2006 Aug 16;26(33):8428-40.

33.

Enhanced odor discrimination and impaired olfactory memory by spatially controlled switch of AMPA receptors.

Shimshek DR, Bus T, Kim J, Mihaljevic A, Mack V, Seeburg PH, Sprengel R, Schaefer AT.

PLoS Biol. 2005 Nov;3(11):e354. Epub 2005 Oct 18.

34.

Impaired reproductive behavior by lack of GluR-B containing AMPA receptors but not of NMDA receptors in hypothalamic and septal neurons.

Shimshek DR, Bus T, Grinevich V, Single FN, Mack V, Sprengel R, Spergel DJ, Seeburg PH.

Mol Endocrinol. 2006 Jan;20(1):219-31. Epub 2005 Aug 11.

PMID:
16099814
35.

A genetic switch for epilepsy in adult mice.

Krestel HE, Shimshek DR, Jensen V, Nevian T, Kim J, Geng Y, Bast T, Depaulis A, Schonig K, Schwenk F, Bujard H, Hvalby Ø, Sprengel R, Seeburg PH.

J Neurosci. 2004 Nov 17;24(46):10568-78.

36.

ER-based double iCre fusion protein allows partial recombination in forebrain.

Casanova E, Fehsenfeld S, Lemberger T, Shimshek DR, Sprengel R, Mantamadiotis T.

Genesis. 2002 Nov;34(3):208-14. Erratum in: Genesis. 2002 Dec;34(4):267.

PMID:
12395386
37.

Codon-improved Cre recombinase (iCre) expression in the mouse.

Shimshek DR, Kim J, Hübner MR, Spergel DJ, Buchholz F, Casanova E, Stewart AF, Seeburg PH, Sprengel R.

Genesis. 2002 Jan;32(1):19-26.

PMID:
11835670
38.

Using reporter genes to label selected neuronal populations in transgenic mice for gene promoter, anatomical, and physiological studies.

Spergel DJ, Krüth U, Shimshek DR, Sprengel R, Seeburg PH.

Prog Neurobiol. 2001 Apr;63(6):673-86. Review.

PMID:
11165000
39.

Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice.

Scheja L, Makowski L, Uysal KT, Wiesbrock SM, Shimshek DR, Meyers DS, Morgan M, Parker RA, Hotamisligil GS.

Diabetes. 1999 Oct;48(10):1987-94.

PMID:
10512363

Supplemental Content

Loading ...
Support Center